uric acid and Cough
uric acid has been researched along with Cough in 4 studies
Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.
uric acid : An oxopurine that is the final oxidation product of purine metabolism.
6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.
7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.
Cough: A sudden, audible expulsion of air from the lungs through a partially closed glottis, preceded by inhalation. It is a protective response that serves to clear the trachea, bronchi, and/or lungs of irritants and secretions, or to prevent aspiration of foreign materials into the lungs.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the efficacy and safety of febuxostat extended release (XR) and immediate release (IR) in patients with gout and normal or impaired renal function." | 9.30 | Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase III Placebo-Controlled Study. ( Becker, MA; Castillo, M; Gunawardhana, L; Hunt, B; Kisfalvi, K; Saag, KG; Whelton, A, 2019) |
| "To assess the efficacy and safety of febuxostat extended release (XR) and immediate release (IR) in patients with gout and normal or impaired renal function." | 5.30 | Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase III Placebo-Controlled Study. ( Becker, MA; Castillo, M; Gunawardhana, L; Hunt, B; Kisfalvi, K; Saag, KG; Whelton, A, 2019) |
| "Enalapril has similar effects to losartan on systemic blood pressure, renal function and serum UA in patients with CKD, but carries a higher risk of dry cough." | 4.89 | Enalapril versus losartan for adults with chronic kidney disease: a systematic review and meta-analysis. ( Feng, L; He, YM; Huo, DM; Liao, YH; Yang, ZH, 2013) |
Research
Studies (4)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Saag, KG | 1 |
| Becker, MA | 1 |
| Whelton, A | 1 |
| Hunt, B | 1 |
| Castillo, M | 1 |
| Kisfalvi, K | 1 |
| Gunawardhana, L | 1 |
| He, YM | 1 |
| Feng, L | 1 |
| Huo, DM | 1 |
| Yang, ZH | 1 |
| Liao, YH | 1 |
| Friedman, GD | 1 |
| Siegelaub, AB | 1 |
| Shionoiri, H | 1 |
| Sugimoto, K | 1 |
| Kosaka, T | 1 |
| Kita, E | 1 |
| Oda, H | 1 |
| Ushikubo, T | 1 |
| Goto, T | 1 |
| Takasaki, I | 1 |
| Yasuda, G | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout[NCT02139046] | Phase 3 | 1,790 participants (Actual) | Interventional | 2014-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Trial Outcomes
Percentage of Participants With at Least One Gout Flare Requiring Treatment
"A participant was considered to have a gout flare if the following criteria were met:~Participant-reported acute particular pain typical of a gout attack that was deemed by participant and/or investigator to require treatment and was treated with colchicine, nonsteroidal anti-inflammatory drugs (NSAIDs) or steroids, Participant experienced at least 3 or more of: 1) Joint swelling, 2) Redness, 3) Tenderness, 4) Pain, Participant experienced at least one or more of: 1) Rapid onset of pain, 2) Decreased range of motion, 3) Joint warmth, 4) Other symptoms similar to a prior gout flare." (NCT02139046)
Timeframe: Baseline to Month 3
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 20.7 |
| Febuxostat IR 40 mg | 21.0 |
| Febuxostat XR 40 mg | 22.8 |
| Febuxostat IR 80 mg | 27.2 |
| Febuxostat XR 80 mg | 26.6 |
Percentage of Participants With Serum Urate <5.0 mg/dL at Month 3
(NCT02139046)
Timeframe: Month 3
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 0.3 |
| Febuxostat IR 40 mg | 15.7 |
| Febuxostat XR 40 mg | 25.9 |
| Febuxostat IR 80 mg | 42.6 |
| Febuxostat XR 80 mg | 50.1 |
Percentage of Participants With Serum Urate <6.0 mg/dL at Month 3
(NCT02139046)
Timeframe: Month 3
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 0.6 |
| Febuxostat IR 40 mg | 40.3 |
| Febuxostat XR 40 mg | 48.2 |
| Febuxostat IR 80 mg | 57.7 |
| Febuxostat XR 80 mg | 61.1 |
Reviews
1 review available for uric acid and Cough
| Article | Year |
|---|---|
Enalapril versus losartan for adults with chronic kidney disease: a systematic review and meta-analysis.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biom | 2013 |
Trials
2 trials available for uric acid and Cough
| Article | Year |
|---|---|
Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase III Placebo-Controlled Study.
Topics: Adult; Aged; Alanine Transaminase; Aspartate Aminotransferases; Colchicine; Cough; Creatinine; Delay | 2019 |
Long-term therapy with an ACE inhibitor, temocapril, reduces microalbuminuria in essential hypertension.
Topics: Albuminuria; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Cough; | 1998 |
Other Studies
1 other study available for uric acid and Cough
| Article | Year |
|---|---|
Changes after quitting cigarette smoking.
Topics: Adult; Aged; Angina Pectoris; Blood Glucose; Blood Pressure; Cholesterol; Chronic Disease; Coronary | 1980 |